Advertisement

Topics

Innophos Holdings, Inc. Reports Second-Quarter 2017 Results

03:18 EDT 1 Aug 2017 | PR Newswire

CRANBURY, N.J., Aug. 1, 2017 /PRNewswire/ -- Innophos Holdings, Inc. (NASDAQ:  IPHS) today announced its financial results for the second quarter ended June 30, 2017. In a separate press release, Innophos announced today that it has entered into a definitive merger agreement to acquire Novel Ingredients, a New Jersey-based provider of dietary supplement ingredient solutions.

Highlights

  • Q2 revenue and earnings performance exceeded expectations
  • All segments showed positive year-over-year volume comparisons
  • Delivered final $2 million of $16 million procurement savings pipeline from Phase 1 Operational Excellence initiatives
  • H2 2017 on track to realize $5 million of the identified $13 million Phase 2 Operational Excellence cost savings in the areas of MRO, packaging and logistics
  • Reiterates full year 2017 revenue and earnings guidance, excluding impact of Novel Ingredients acquisition
  • The acquisition of Novel Ingredients will create a Food, Health and Nutrition (FHN) platform of nearly $0.5 billion in revenue representing 60% of total sales. The combined Company will benefit from leading, innovative technology; a broader and deeper product portfolio; and access to new market segments. Please see the Company's Novel Ingredients press release issued today for more details

"We delivered a very robust second quarter with top and bottom line results above our expectations," said Kim Ann Mink, Ph.D., Chairman, President and Chief Executive Officer. "By remaining focused on cost savings from performance improvement initiatives, we grew margins on a year-over-year basis despite continuing market pressure. As we transition into the second half of the year, we are encouraged by several recent developments, including improvements in sales volume. We are confident in our ability to deliver on a strong second half of the year and are reiterating our guidance, excluding the Novel Ingredients acquisition.

"Executing against our Operational Excellence and Commercial Excellence pillars remains paramount to our strategy," continued Mink. "We now have completed our Phase 1 Operational Excellence efforts and are on schedule to begin delivering Phase 2 savings in the third quarter. We continue to look at additional opportunities to achieve further productivity improvements in 2018 and beyond, including in the areas of manufacturing optimization and strategic supply chain enhancements.

"Under the Strategic Growth pillar, we took a significant step forward toward achieving our Vision 2022 goals with our announced acquisition of Novel Ingredients, which creates a $0.5 billion FHN platform," continued Mink.  "With an enhanced set of innovative products and capabilities that serve high-growth nutrition markets, we are strengthening our ability to deliver value to our customers, more closely aligning Innophos with consumer mega-trends such as health and wellness, energized aging, and clean labels, and advancing toward our goal to be a leading specialty ingredient solutions provider to attractive FHN markets." 

Second Quarter Results Variance $ and Variance % in the following tables may not foot due to rounding

$ Millions except EPS

Quarter 2

2017

2016

Variance $

Variance %

Sales

179

182

(3)

(2)%

Net Income

11

12

(1)

(7)%

Adj. Net Income

11

12

(1)

(8)%

EBITDA

28

28

--

(1)%

Adj. EBITDA

30

30

--

--

Diluted EPS

0.57

0.61

(0.05)

(8)%

Adj. Diluted EPS

0.57

0.63

(0.05)

(8)%

Cash from Ops

30

45

(15)

(33)%

Free Cash Flow

23

35

(12)

(35)%

  • Q2 earnings performance exceeded guidance due to strong sales performance. Adjusted EBITDA of $30 million yielded a margin of 17%, up 18 basis points versus prior year.
  • Sales volume was 3% higher year over year, with all segments recording positive variances, and up 8% sequentially.
  • Operational Excellence initiatives continued to make a strong contribution with favorable input costs more than offsetting lower selling prices.
  • Net income and EPS were adversely affected by a higher effective tax rate of 34% in the quarter from a strengthened Mexican peso and general inflation.
  • Cash flow was positive with continued working capital improvements and a low capital expenditure run rate. Cash flow was down year over year due to higher working capital improvements in Q2 2016.
  • Capex was down versus the prior-year quarter despite the strategic investment in the Geismar deep well, which represents approximately 30% of total quarterly spend.

Q2 Segment Financials

Sales

2017 $ Millions

2016 $ Millions

Variance $

Variance %

FHN

92

95

(2)

(3)%

IS

67

72

(5)

(6)%

Other

20

15

4

28%

Total Innophos

179

182

(3)

(2)%

Adj. EBITDA

2017 $ Millions

2016 $ Millions

2017 Margin

2016 Margin

FHN

18

20

20%

22%

IS

10

11

14%

15%

Other

2

(1)

12%

(8)%

Total IPHS

30

30

17%

17%

Note: See Adjusted EBITDA reconciliation to EBITDA in the financial tables that follow

  • Sales volume was up across all segments compared with the prior-year quarter, offset by price erosion in line with expectations. FHN sales represented 51% of total Company sales.
  • FHN Q2 EBITDA margins were strong at 20%, and improved 138 basis points sequentially.
  • IS margins declined 78 basis points versus Q2 2016 due to lower average selling prices, partially offset by improved mix from product pruning and cost controls.
  • Other margins were 12%, a significant improvement compared with negative 8% for the same period last year.

Year-to-date Results Variance $ and Variance % in the following tables may not foot due to rounding

$ Millions except EPS

YTD Quarter 2

2017

2016

Variance $

Variance %

Sales

345

371

(26)

(7)%

Net Income

22

25

(3)

(11)%

Adj. Net Income

23

25

(2)

(9)%

EBITDA

54

59

(5)

(9)%

Adj. EBITDA

58

61

(4)

(6)%

Diluted EPS

1.12

1.27

(0.15)

(12)%

Adj. Diluted EPS

1.16

1.28

(0.12)

(9)%

Cash from Ops

19

42

(23)

(54)%

Free Cash Flow

3

24

(21)

(86)%

  • YTD Sales variance improved sequentially by 540 basis points. H1 year-over-year comparisons were adversely affected by H2 2016 pruning actions management took on lower margin, less differentiated applications.
  • Adjusted EBITDA margin was up 19 basis points versus the prior-year period due to savings from Phase 1 Operational Excellence initiatives.
  • Average working capital improved by $30 million, or 16% versus prior year.

YTD Quarter 2 Segment Financials

Sales

2017 $ Millions

2016 $ Millions

Variance $

Variance %

FHN

183

193

(10)

(5)%

IS

131

147

(15)

(11)%

Other

31

32

(1)

(4)%

Total Innophos

345

372

(26)

(7)%

Adj. EBITDA

2017 $ Millions

2016 $ Millions

2017 Margin

2016 Margin

FHN

35

41

19%

21%

IS

20

20

15%

14%

Other

3

--

11%

--

Total IPHS

58

61

17%

16%

Note: See Adjusted EBITDA reconciliation to EBITDA in the financial tables that follow

  • FHN YTD sales were down 5%, primarily due to lower export sales to Health end-markets, which had an adverse effect on average selling prices and segment profitability.
  • IS YTD sales were primarily affected by H2 2016 pruning actions, resulting in improved adjusted EBITDA margins.
  • Other sales were essentially flat year over year, benefiting at the adjusted EBITDA level from the new tolling arrangement.

Recent Trends and Outlook 

Q3 2017 Sales in Q3 are expected to be similar to the second quarter 2017, down approximately 4% year over year, but with an anticipated mix improvement towards FHN.

Earnings in the third quarter are forecast to be positively affected sequentially by reduced implementation fees and first-time cost savings from Phase 2 operational excellence. Input costs are otherwise expected to be in line with second quarter 2017.

The Company anticipates that the tax rate will be at the more normalized level of approximately 33% in the third quarter.

Full Year 2017The Company is reiterating its revenue and earnings guidance for full year 2017, excluding the impact of the Novel Ingredients acquisition. 

On a full-year basis, overall market conditions and the competitive landscape for 2017 are expected to be similar to 2016.

The Company anticipates that the Phase 2 Operational Excellence fees incurred in the first half of the year will be more than offset by the Phase 2 savings, of which $5 million is estimated to take effect in the second half of 2017.

As a result of these factors, the Company continues to expect full-year revenues to be down by approximately 4% compared with 2016. The Company further continues to expect full-year earnings to be broadly in line with 2016, reflecting the impact of management's focus on cost actions and productivity initiatives given the challenging market conditions.

Conference Call

Innophos will host its second quarter 2017 conference call on Tuesday, August 1, 2017 at 9:00 am ET to discuss its earnings results and the Novel Ingredients acquisition. The call can be accessed by dialing 1-800-708-4539 (U.S.) or 1-847-619-6396 (international) and entering passcode 4532-6485. Please dial in approximately 15 minutes ahead of the start time to ensure timely entry to the call. The Q2 2017 earnings call presentation will be made available on the Company's website the morning of the call. A replay will be available between 11:30 am ET on August 1 and 11:59 pm ET on August 15, 2017. The replay is accessible by dialing 1-888-843-7419 (U.S.) or 1-630-652-3042 (international) and entering passcode 4532-6485#. Additional information on Innophos' second quarter results can also be found on the Company's website.

About the Company

Innophos is a leading international producer of specialty ingredient solutions that deliver far-reaching, versatile benefits for the food, health, nutrition and industrial markets. We leverage our expertise in the science and technology of blending and formulating phosphate, mineral and botanical based ingredients to help our customers offer products that are tasty, healthy, nutritious and economical. Headquartered in Cranbury, New Jersey, Innophos has manufacturing operations across the United States, in Canada, Mexico and China. For more information, please visit www.innophos.com. 'IPHS-G'

Financial Tables Follow

Safe Harbor for Forward-Looking and Cautionary Statements

This press release contains or may contain forward-looking statements within the meaning of Section 27a of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends these forward-looking statements to be covered by the safe harbor provisions for such statements. Statements made in this press release that relate to our future performance or future financial results or other future events (which may be identified by such terms as "expect", "estimate", "anticipate",  "assume", "believe", "plan", "intend', "may", "will", "should", "outlook", "guidance", "target", "opportunity", "potential" or similar terms and variations  or the negative thereof) are forward-looking statements, including the Company's expectations regarding the business environment and the Company's overall guidance regarding future performance and growth. These statements are based on our current beliefs and expectations and are subject to significant risks and uncertainties. Actual results may materially differ from the expectations expressed in or implied by these forward-looking statements. Factors that could cause the Company's actual results to differ materially include, but are not limited to: (1) global macroeconomic conditions and trends; (2) the behavior of financial markets, including fluctuations in foreign currencies, interest rates and turmoil in capital markets; (3) changes in regulatory controls regarding tariffs, duties, taxes and income tax rates; (4) the Company's ability to implement and refine its Vision 2022; (5) the Company's ability to successfully identify and complete acquisitions in line with its Vision 2022 and effectively operate and integrate acquired businesses to realize the anticipated benefits of those acquisitions; (5) the Company's ability to realize expected cost savings and efficiencies from its performance improvement and other optimization initiatives; (6) the Company's ability to effectively compete in its markets, and to successfully develop new and competitive products that appeal to its customers; (7) changes in consumer preferences and demand for the Company's products or a decline in consumer confidence and spending; (8) the Company's ability to benefit from its investments in assets and human capital and the ability to complete projects successfully and on budget; (9) economic, regulatory and political risks associated with the Company's international operations, most notably Mexico and China; (10) volatility and increases in the price of raw materials, energy and transportation, and fluctuations in the quality and availability of raw materials and process aids; (11) the impact of a disruption in the Company's supply chain or its relationship with its suppliers; (12) the Company's ability to comply with, and the costs associated with compliance with, U.S. and foreign environmental protection laws; (13) the Company's ability to meet quality and regulatory standards in the various jurisdictions in which it has operations or conducts business and (14) the Company's ability to consummate the acquisition of Novel Ingredients and to achieve the benefits anticipated from such acquisition. We caution you to consider the important risks and other factors as set forth in the forward-looking statements section and in Item 1A Risk Factors in our most recent Annual Report on Form 10-K, as amended by subsequent reports on Forms 10-Q and 8-K. We do not undertake to update the forward-looking statements to reflect the impact of circumstances or events that may arise after the date of the forward-looking statements.

Summary Profit & Loss Statement

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Statement of Operations (Unaudited)

(Dollars In thousands, except per share amounts or share amounts)

 

Three Months Ended June 30,

 

Six Months Ended June 30,

2017

2016

2017

2016

Net sales

$179,140

$181,888

$345,084

$371,518

Cost of goods sold

140,064

145,738

269,465

294,652

Gross profit

39,076

36,150

75,619

76,866

Operating expenses:

     Selling, general and administrative

19,867

15,732

39,175

33,967

     Research & development expenses

818

1,021

1,648

2,017

     Total operating expenses

20,685

16,753

40,823

35,984

Operating income

18,391

19,397

34,796

40,882

Interest expense, net

1,452

1,913

2,805

3,712

Foreign exchange loss (gain)

(78)

355

(135)

316

Income before income taxes

17,017

17,129

32,126

36,854

Provision for income taxes

5,794

5,025

9,980

11,908

Net income

$11,223

$12,104

$22,146

$24,946

Diluted Earnings Per Participating Share

$0.57

$0.61

$1.12

$1.27

Diluted weighted average participating shares outstanding

19,692,690

19,613,807

19,693,682

19,521,960

Dividends paid per share of common stock

$0.48

$0.48

$0.96

$0.96

Dividends declared per share of common stock

$0.48

$0.48

$0.96

$0.96

Adjusted EBITDA Reconciliation to Net Income

(Dollars in thousands)

 

Three Months Ended June 30,

 

Six Months Ended June 30,

2017

2016

2017

2016

Net Income

$11,223

$12,104

$22,146

$24,946

Interest expense, net

1,452

1,913

2,805

3,712

Provision for income taxes

5,794

5,025

9,980

11,908

Depreciation & amortization

9,550

9,282

19,131

18,564

EBITDA

28,019

28,324

54,062

59,130

Adjustments

Non-cash stock compensation *

1,568

1,292

2,285

1,826

Foreign exchange loss (gain)

(78)

355

(135)

316

Severance/Restructuring expense (income)

326

-

1,326

(43)

Adjusted EBITDA

$29,835

$29,971

$57,538

$61,229

Percent of Sales

16.7%

16.5%

16.7%

16.5%

* Not adjusted when calculating Adjusted EPS

Adjusted Net Income Reconciliation to Net Income

(Dollars in thousands, except EPS)

Three Months Ended June 30,

Six Months Ended June 30,

2017

2016

2017

2016

Net Income (loss)

$11,223

$12,104

$22,146

$24,946

Pre-tax Adjustments

Foreign exchange loss (gain)

(78)

355

(135)

316

Severance/Restructuring expense (income)

326

-

1,326

(43)

Total Pre-tax Adjustments

248

355

1,191

273

Income tax effects on Adjustments

84

104

346

76

Adjusted Net Income

$11,387

$12,355

$22,991

$25,143

Adjusted Diluted Earnings
Per Participating Share

$0.57

$0.63

$1.16

$1.28

Segment Adjusted EBITDA Reconciliation to EBITDA

(Dollars in thousands)

Three Months Ended June 30, 2017

Three Months Ended June 30, 2016

    FHN   

      IS     

  Other  

   Total   

    FHN   

      IS     

  Other  

   Total   

EBITDA

$17,032

$8,654

$2,333

$28,019

$19,744

$10,136

($1,556)

$28,324

Non-cash stock compensation

887

621

60

1,568

732

534

26

1,292

Foreign exchange loss (gain)

(26)

0

(52)

(78)

0

0

355

355

Severance/Restructuring exp.(inc.)

130

196

0

326

0

0

0

0

Adjusted EBITDA

$18,023

$9,471

$2,341

$29,835

$20,476

$10,670

($1,175)

$29,971

Six Months Ended June 30, 2017

Six Months Ended June 30, 2016

    FHN   

      IS     

  Other  

   Total   

    FHN   

      IS     

  Other  

   Total   

EBITDA

$32,656

$18,175

$3,231

$54,062

$39,677

$19,697

($244)

$59,130

Non-cash stock compensation

1,293

905

87

2,285

1,039

715

72

1,826

Foreign exchange loss (gain)

(30)

0

(105)

(135)

0

0

316

316

Severance/Restructuring exp.(inc.)

665

635

26

1,326

145

0

(188)

(43)

Adjusted EBITDA

$34,584

$19,715

$3,239

$57,538

$40,861

$20,412

($44)

$61,229

Cash From Operations Reconciliation to EBITDA 

(Dollars in thousands)

 

Three Months Ended June 30,

 

Six Months Ended June 30,

2017

2016

2017

2016

EBITDA

$28,019

$28,324

$54,062

$59,130

Operating Working Capital

7,840

24,987

(21,382)

13,701

Taxes paid

(5,940)

(6,425)

(11,365)

(26,443)

Interest paid

(1,380)

(1,788)

(2,685)

(3,498)

All other including non-cash stock compensation and changes in other     
long-term assets and liabilities

1,496

15

726

(851)

Net cash provided from operations

$30,035

$45,113

$19,356

$42,039

Cash From Operations Reconciliation to Adjusted EBITDA 

(Dollars in thousands)

 

Three Months Ended June 30,

 

Six Months Ended June 30,

2017

2016

2017

2016

Adjusted EBITDA

$29,835

$29,971

$57,538

$61,229

Operating Working Capital

7,592

24,632

(22,573)

13,428

Taxes paid

(5,940)

(6,425)

(11,365)

(26,443)

Interest paid

(1,380)

(1,788)

(2,685)

(3,498)

All other including changes in other     
long-term assets and liabilities

(72)

(1,277)

(1,559)

(2,677)

Net cash provided from operations

$30,035

$45,113

$19,356

$42,039

Free Cash Flow Reconciliation to Cash From Operations

Three Months Ended June 30,

Six Months Ended June 30,

(Dollars in thousands)

2017

2016

2017

2016

Cash From Operations

$30,035

$45,113

$19,356

$42,039

Capital Expenditures

(7,524)

(10,514)

(16,077)

(18,538)

Free Cash Flow

$22,511

$34,599

$3,279

$23,501

Segment Reporting – Second Quarter

Three Months Ended June 30,

Net Sales

2017

2016

% Change

Segment Net Sales

Food, Health and Nutrition

$92,198

$94,662

(2.6)%

Industrial Specialties

67,368

71,912

(6.3)%

Other

19,574

15,314

27.8%

Total

$179,140

$181,888

(1.5)%

Segment EBITDA

Food, Health and Nutrition

$17,032

$19,744

Industrial Specialties

8,654

10,136

Other

2,333

(1,556)

Total

$28,019

$28,324

Segment EBITDA % of net sales

Food, Health and Nutrition

18.5%

20.9%

Industrial Specialties

12.8%

14.1%

Other

11.9%

(10.2)%

Total

15.6%

15.6%

Depreciation and amortization expense

Food, Health and Nutrition

$5,498

$5,252

Industrial Specialties

3,486

3,538

Other

566

492

Total

$9,550

$9,282

Segment Reporting – Year-to-date

 

Six Months Ended June 30,

Net Sales

2017

2016

% Change

Segment Net Sales

Food, Health and Nutrition

$183,281

$193,074

(5.1)%

Industrial Specialties

131,040

146,467

(10.5)%

Other

30,763

31,977

(3.8)%

Total

$345,084

$371,518

(7.1)%

Segment EBITDA

Food, Health and Nutrition

$32,656

$39,677

Industrial Specialties

18,175

19,697

Other

3,231

(244)

Total

$54,062

$59,130

Segment EBITDA % of net sales

Food, Health and Nutrition

17.8%

20.6%

Industrial Specialties

13.9%

13.4%

Other

10.5%

(0.8)%

Total

15.7%

15.9%

Depreciation and amortization expense

Food, Health and Nutrition

$11,220

$10,043

Industrial Specialties

6,858

6,597

Other

1,053

1,924

Total

$19,131

$18,564

Price / Volume

The Company calculates pure selling price dollar variances as the selling price for the current year to date period minus the selling price for the prior year to date period, and then multiplies the resulting selling price difference by the prior year to date period volume. The current quarter selling price dollar variance is derived from the current quarter year to date selling price dollar variance less the previous quarter year to date selling price dollar variance. The selling price dollar variance is then divided by the prior period sales dollars to calculate the percentage change. Volume variance is calculated as the total sales variance minus the selling price variance and refers to the revenue effect of changes in tons sold at the relative prices applicable to the variation in tons, otherwise known as volume/mix.

The following table illustrates the percentage changes in net sales by reportable segments compared with the same period of the prior year, including the effect of selling price and volume/mix changes upon revenue:

Three Months Ended March 31, 2017

Six Months Ended June 30, 2017

Reportable Segments

  Price  

Volume/Mix

  Total  

  Price  

Volume/Mix

  Total  

Food, Health and Nutrition

(4.5)%

1.9%

(2.6)%

(3.7)%

(1.4)%

(5.1)%

Industrial Specialties

(6.5)%

0.2%

(6.3)%

(6.8)%

(3.7)%

(10.5)%

Other

(2.7)%

30.5%

27.8%

(6.9)%

3.1%

(3.8)%

Total

(5.1)%

3.6%

(1.5)%

(5.2)%

(1.9)%

(7.1)%

Summary Cash Flow Statement 

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited)

(Dollars in thousands)

Six Months Ended June 30,

2017

2016

Cash flows provided from operating activities

     Net income

$22,146

$24,946

     Adjustments to reconcile net income to net cash provided from

     operating activities:

          Depreciation and amortization

19,131

18,564

          Amortization of deferred financing charges

215

337

          Deferred income tax provision

14

363

          Gain on sale of building

(153)

-

          Share-based compensation

2,285

1,301

     Changes in assets and liabilities:

         Increase in accounts receivable

(7,797)

(5,302)

         Decrease in inventories

1,650

16,480

         (Increase) decrease in other current assets

(5,975)

5,947

         (Decrease) increase in accounts payable

(6,389)

2,328

         Decrease in other current liabilities

(2,688)

(18,327)

         Changes in other long-term assets and liabilities

(3,083)

(4,598)

              Net cash provided from operating activities

19,356

42,039

Cash flows used for investing activities:

      Capital expenditures

(16,077)

(18,538)

      Proceeds from sale of building

1,028

-

             Net cash used for investing activities

(15,049)

(18,538)

Cash flows used for financing activities:

     Proceeds from exercise of stock options

-

9

     Long-term debt borrowings

14,000

36,000

     Long-term debt repayments

(19,000)

(19,002)

     Excess tax (deficiency) benefit from exercise of stock options

-

(331)

     Restricted stock forfeitures

(738)

(318)

     Dividends paid

(18,722)

(18,564)

            Net cash used for financing activities

(24,460)

(2,206)

Effect of foreign exchange rate changes on cash and cash equivalents

162

12

Net change in cash

(19,991)

21,307

Cash and cash equivalents at beginning of period

53,487

17,905

Cash and cash equivalents at end of period

$33,496

$39,212

Summary Balance Sheets 

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited)

(Dollars In thousands)

June 30,
2017

December 31,
2016

ASSETS

Current assets:

     Cash and cash equivalents

$33,496

$53,487

     Accounts receivable, net

85,493

77,692

     Inventories

126,652

128,295

     Other current assets

30,090

23,894

               Total current assets

275,731

283,368

Property, plant and equipment, net

206,683

205,459

Goodwill

84,373

84,373

Intangibles and other assets, net

64,889

69,811

               Total assets

$631,676

$643,011

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

     Accounts payable, trade and other

$45,458

$51,611

     Other current liabilities

40,934

43,605

               Total current liabilities

86,392

95,216

Long-term debt

180,000

185,000

Other long-term liabilities

14,139

15,569

               Total stockholders' equity

351,145

347,226

               Total liabilities and stockholders' equity

$631,676

$643,011

Additional Information

Net debt is a supplemental financial measure that is not required by, or presented in accordance with, US GAAP. The Company believes net debt is helpful in analyzing leverage and as a performance measure for purposes of presentation in this release. The Company defines net debt as total long-term debt (including any current portion) less cash and cash equivalents.

Free cash flow is a supplemental financial measure that is not required by, or presented in accordance with, US GAAP. The Company believes free cash flow is helpful in analyzing the cash flow generating capability of the business and as a performance measure for purposes of presentation in this release. The Company defines free cash flow as net cash provided from operating activities plus cash used for capital expenditures.

EBITDA, adjusted EBITDA, adjusted net income and adjusted diluted EPS are supplemental financial measures that are not required by, or presented in accordance with, US GAAP. The Company believes EBITDA and adjusted EBITDA are helpful in analyzing the cash flow generating capability of the business and as performance measures for purposes of presentation in this release.

Net Working Capital is a supplemental financial measure that is not required by, or presented in accordance with, US GAAP. The Company believes net working capital is helpful in analyzing the effects on the cash flow generating capability of the business and as a performance measure for purposes of presentation in this release. The Company defines net working capital as total current assets less cash less total current liabilities.  

Operating Working Capital is a supplemental financial measure that is not required by, or presented in accordance with, US GAAP. The Company believes operating working capital is helpful in analyzing the effects on the cash flow generating capability of the business and as a performance measure for purposes of presentation in this release. The Company defines operating working capital as net working capital less taxes less interest.

Innophos is not able to provide a reconciliation of its 2022 expectation for Adjusted EBITDA margin to GAAP net income due to the number of variables in the projected EBITDA margin for 2022 and because we are currently unable to quantify accurately certain amounts that would be required to be included in GAAP net income or the individual adjustments for such reconciliation. In addition, we believe such reconciliation would imply a degree of precision that would be confusing or misleading to investors.

Investor Contact                                                                      

Media Contact

Mark Feuerbach                                                                       

Ryan Flaim

Innophos                                                                                 

Sharon Merrill Associates

609-366-1204                                                                            

617-542-5300

investor.relations@innophos.com                                             

iphs@investorrelations.com

View original content:http://www.prnewswire.com/news-releases/innophos-holdings-inc-reports-second-quarter-2017-results-300496989.html

SOURCE Innophos Holdings, Inc.

NEXT ARTICLE

More From BioPortfolio on "Innophos Holdings, Inc. Reports Second-Quarter 2017 Results"

Quick Search
Advertisement
 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...